Pfizer Inc. said on Nov. 14 that it launched the anemia drug Retacrit – the first US biosimilar for Amgen Inc.'s Epogen and Johnson & Johnson's Procrit – at 33.5% and 57.1% discounts, respectively, to the reference products as it gears up to win share in a market where competition already is fierce.
Epogen (epoetin alfa) sales have been in decline for the past few years due to biosimilars outside the US and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?